For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
27
references
 Top references
cited by
14
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      3,272
      similar
       All similar
      • Record: found
      • Abstract: not found
      • Article: not found

      Empagliflozin after Acute Myocardial Infarction

      Author(s): 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1
      Publication date (Electronic):
      Journal: New England Journal of Medicine
      Publisher: Massachusetts Medical Society

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

          Bernard Zinman, Christoph Wanner, John M. Lachin … (2015)
          The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
          Article 0 comments Cited 2555 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

            Milton Packer, Stefan D. Anker, Javed Butler … (2020)
            Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction.
            Article 0 comments Cited 1625 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Empagliflozin in Heart Failure with a Preserved Ejection Fraction

              Stefan D. Anker, Javed Butler, Gerasimos Filippatos … (2022)
              Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain.
              Article 0 comments Cited 1270 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Josephine Harrington: (View ORCID Profile)
                Tomasz Gasior: (View ORCID Profile)
                Xavier Rossello: (View ORCID Profile)
                P. Gabriel Steg: (View ORCID Profile)
                Journal
                Title: New England Journal of Medicine
                Abbreviated Title: N Engl J Med
                Publisher: Massachusetts Medical Society
                ISSN (Print): 0028-4793
                ISSN (Electronic): 1533-4406
                Publication date (Electronic): April 06 2024
                Affiliations
                [1 ]From Baylor Scott and White Research Institute, Dallas (J. Butler); the Department of Medicine, University of Mississippi, Jackson (J. Butler); the Division of Cardiology, Department of Medicine, Duke University Medical Center (W.S.J., J.H., A.F.H.), and the Duke Clinical Research Institute (R.D.L.) — both in Durham, NC; Women’s College Hospital (J.A.U.), the Peter Munk Cardiac Centre, University Health Network, University of Toronto (J.A.U., S.G.G.), and the Division of Cardiology, Department of...
                Article
                DOI: 10.1056/NEJMoa2314051
                PubMed ID: 38587237
                SO-VID: 5e4764ed-2892-4fd9-9e0e-e2b613f7174c
                Copyright © © 2024
                License:

                http://www.nejmgroup.org/legal/terms-of-use.htm

                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content3,272

                See all similar

                Cited by14

                See all cited by

                Most referenced authors504

                See all reference authors